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Background: The therapeutic potential of bacteriophages has been debated since their ﬁrst isolation and
characterisation in the early 20th century. However, a lack of consistency in application and observed efﬁcacy during
their early use meant that upon the discovery of antibiotic compounds research in the ﬁeld of phage therapy quickly
slowed. The rise of antibiotic resistance in bacteria and improvements in our abilities to modify and manipulate DNA,
especially in the context of small viral genomes, has led to a recent resurgence of interest in utilising phage as
antimicrobial therapeutics.
Results: In this article a number of results from the literature that have aimed to address key issues regarding the
utility and efﬁcacy of phage as antimicrobial therapeutics utilising molecular biology and synthetic biology
approaches will be introduced and discussed, giving a general view of the recent progress in the ﬁeld.
Conclusions: Advances in molecular biology and synthetic biology have enabled rapid progress in the ﬁeld of phage
engineering, with this article highlighting a number of promising strategies developed to optimise phages for the
treatment of bacterial disease. Whilst many of the same issues that have historically limited the use of phages as
therapeutics still exist, these modiﬁcations, or combinations thereof, may form a basis upon which future advances
can be built. A focus on rigorous in vivo testing and investment in clinical trials for promising candidate phages may
be required for the ﬁeld to truly mature, but there is renewed hope that the potential beneﬁts of phage therapy may
ﬁnally be realised.
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INTRODUCTION 1
The viruses of bacteria, or bacteriophages (phages), have
a long and storied history [1] with even their initial
identiﬁcation becoming a matter of some debate. The
earliest known observation of what we would now
consider to be a bacteriophage is ascribed to Frederick
Twort [2], but the recognition of phages as a biological
entity more in line with our current understanding is
found in independent observations by Félix d’Herelle [3].
The contentiousness of phage spreads beyond their
discovery, with questions regarding their efﬁcacy and
usefulness as treatment for bacterial disease persisting
from their initial use in the 1920’s to the modern day.
This article is dedicated to the Special Collection of Synthetic Biology,
Aiming for Quantitative Control of Cellular Systems (Eds. Cheemeng
Tan and Haiyan Liu).
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There are two major reasons for this scepticism regarding
the use of phage as therapeutic agents; ﬁrstly that their
initial use was not always well regulated or documented
in the English language and often highly regional [4], and
secondly that in the antibiotic-era there has been little
need for further investigation of a treatment method that is
likely to be less reproducible, cost-effective, and
efﬁcacious than treatment of bacterial disease with
antibiotic drugs. This lack of investment and testing
means that many questions still remain open regarding the
potential of phage therapy as a microbial control and
treatment method, especially in the context of modern
pharmaceuticals where methods of isolation and puriﬁca-
tion, target speciﬁcity, efﬁcacy, pharmacokinetics, and
safety are all major considerations. These are issues for
which systematic regulated testing methodologies are
well understood in the context of chemical antimicrobial
drugs, but signiﬁcantly less well deﬁned in the context of
replicative biological entities such as bacteriophage.
However, as we approach what may become a post-
antibiotic era of human and veterinary medicine [5,6], the
properties and therapeutic potential of phages has become
an area of active interest. Co-incidentally this increased
focus on phages has arrived at a point where the enabling
effect of improved tools for genetic manipulation and
characterisation are starting to be realised in the ﬁeld of
synthetic biology. Synthetic biology is enabling research-
ers to investigate new methods for controlling biological
systems [7–9] and how best to harness these concepts in
the context of applied research and medicine [10–12]. The
relatively small size of the genomes of phages, and the
relative ease of propagation and manipulation within a
laboratory environment when compared to eukaryotic
viruses, has meant that bacteriophages are ideal candi-
dates for investigation of genetic modiﬁcation of viruses
[13,14], with a speciﬁc focus on whether genetic
modiﬁcation can be useful in the context of generating
phage suitable for treatment of human and veterinary
bacterial diseases [15,16].
Genetic modiﬁcation of phages is speciﬁcally being
applied to address some of the concerns regarding aspects
of their biology that may be important in the context of
treatment of disease. These include modiﬁcation of the
host-range of phages in order to enable targeted treatment
of bacterial populations, methods to increase the persis-
tence of phages within the host and modulation of phage
interactions with the host immune system, and altering the
life-cycle of a phage to minimise the risk of host-toxicity
effects upon lysis of a bacterial population in vivo. This
review will discuss speciﬁc results associated with the
genetic modiﬁcation of phages; speciﬁcally in the context
of the importance of phages as engineered novel anti-
microbial therapeutic agents.
ENGINEERING BACTERIOPHAGE WITH
AN EXPANDED OR ALTERED
HOST-RANGE
One of the major challenges of harnessing bacteriophage
to treat bacterial infection is the huge diversity of both
bacteria and phages. Viral genomes are typically highly
plastic, and possibly due to the interaction of phages with
bacterial species that also show a high degree of genetic
plasticity and adaptability, phages appear to have evolved
in such a way as to become highly speciﬁed infectious
agents. When considering the clinical use of phages this
tightly deﬁned host-range becomes extremely important.
Precise targeting is a prized goal for any treatment
methodology, but when a number of different species and
intra-species variants need to be treated, as would be the
case in the treatment of a typical bacterial infection, there
needs to be ﬂexibility in the system to target a signiﬁcant
proportion of these variants at the infection site. Therefore
investigation into ways to broaden or alter the host-range
of phages is an important step towards their relevance in a
clinical setting.
Attachment and delivery of viral genome to the host is
mediated by the tail ﬁbers and baseplate of phage, with
tail ﬁbers often speciﬁc to a certain bacterial outer
membrane component, and locationally sensitive due to
differing densities of these membrane components at
different sites on the surface of the host. Therefore, these
mediators of attachment and adsorption are ideal targets
when considering methods to alter host-range (Figure 1).
A discussion of the full range of attachment sites available
to bacteriophage is beyond the scope of this article, with a
vast array of host surface components such as ﬂagella,
pili, capsules, lipopolysaccharides and proteins all being
implicated as sites for phage attachment, but a detailed
summary can be found in Rakhuba et al. [17]. The
binding of tail ﬁbers to the cell surface typically takes
place as either an abortive on-off interaction or as an
irreversible/strong interaction, and in many cases it is only
when a certain proportion of tail ﬁbers have been
adsorbed to the cell surface in an irreversible manner
that DNA penetration proceeds [18–24]. The baseplate
also plays a role in attachment and entry, especially in
phages with contractile tail sheaths such as T4-like
phages, where initial binding of long tail ﬁbers leads to a
conﬁrmation change in the baseplate, which both presents
short tail ﬁbers to mediate irreversible binding and
simultaneously contracts the tail sheath to expose the
inner hollow tube and puncture the host cell membrane
ready for genome delivery [25–27].
In the context of bacteriophage therapies, broadening of
host-range was initially achieved by utilising a mixed
population of phages in a single treatment, typically
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Figure 1. Schematics showing three representative methods used to generate or engineer a population of phages with altered or
broadened host-range. The traditional approach to expanding treatment speciﬁcity involves isolating a number of wild-type phages with broadly
similar lytic properties but with different host-speciﬁcities. When these phage are mixed and applied to a bacterial population the diversity of
available host-ranges allows for the concurrent targeting of a number of different bacterial species. A second approach involves using genome
engineering to swap tail ﬁber genes between two phage. Generally this approach will involve swapping tail ﬁbers from a broadly infectious but
poorly lytic (or lysogenic) phage into the genome of a highly lytic phage. By doing this, it is hoped that broad-infectivity is transferred to the
engineered phage through exchanged tail ﬁbers whilst retaining the lytic properties of the wild-type phage, thus expanding the host-range. The
third approach involves randomly altering the tail ﬁber genes of a phage to generate a library of variants. Here, polymerase chain reaction (PCR)
mutagenesis is used to amplify a pool of tail ﬁber variants from the wild-type genome. This gene library can then be subsequently transferred into
the wild-type phage genome by homologous recombination. It is then possible to rescue a library of phages with different tail ﬁber mutations that
can then be screened for the ability to infect a mixed population of bacteria, or for the ability to infect a speciﬁc host that could not be infected by
the wild-type phage.
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called a phage cocktail [28–31] (Figure 1). This
combination method appears to be tested with a high
degree of efﬁcacy, especially in Eastern Europe [4], but it
is perhaps difﬁcult to envisage the transition of such a
treatment strategy into a modern Western regulatory and
manufacturing framework, where the precise quantities
and qualities of each phage would likely need to be
characterised and quantiﬁed pre- and post-mixing.
However, deﬁned methods for phage cocktail design,
isolation and preparation have been developed and this is
still very much a viable strategy for future implementa-
tions of phage therapy [32–36]. However, phage
engineering has aimed to reduce the necessity for delivery
of a diverse population of phage in a cocktail by directly
modifying the mediators of attachment in a lytic phage
‘scaffold’ which can then be used to produce a population
of phages capable of lysing bacteria not typically targeted
by the wild-type ‘scaffold’. Compatibility and conserved
genome organisation between phages allows for the direct
swapping of tail ﬁber genes between phages from
different genera and, due to host-range being closely
correlated with tail ﬁber origin, this has allowed the direct
manipulation of phage host-range (Figure 1). For example
Mahichi et al. demonstrated that transfer of the tail ﬁber
genes gp37 and gp38 from the broadly infectious phage
IP088 to the lytic but narrow-spectrum phage T2 led to an
expansion of the T2 host-range without loss of lytic
function [37]. Similarly, although not an example of host-
range expansion, Yoichi et al. demonstrated that the
ability of phage PP01 to recognise and bind the highly-
pathogenic E. coli O157:H7 could be transferred by
recombination of the gp37 and gp38 genes into T2 [38].
However, whilst the modiﬁed T2 was now able to infect
O157:H7, it presented a smaller plaque phenotype and
lower adsorption efﬁciency with an increase in the
number of phage-resistant bacteria compared to wild-
type PP01. A different strategy has been employed to
modify the host-range of T4, here Pouillot et al. generated
a library of virulent T4 phage capable of infecting a broad
spectrum of bacterial species by utilising random PCR
mutagenesis of gp37 and gp38 followed by homologous
recombination to generate T4 tail ﬁber mutants [39].
However, it should be noted that this paper does not
exhaustively address the question of whether the lytic
properties of the phage are comparable between wild-type
T4 in an E. coli host and the modiﬁed T4 library in
Pseudomonas aeruginosa and Yersinia ruckeri. Phages
T7 and T3 have also been targets for investigation due to
their genome homology and the relatively large historical
body of work regarding their characterisation [40]. A
study by Lin et al. into differences in F-plasmid mediated
genome entry exclusion in phages T7 and T3 when
infecting male (F+, F’, Hfr) and female (F–) strains of
E. coli identiﬁed that recombination between the two
phages led to a T3/7 hybrid containing a T7-like gp17 tail
ﬁber gene [41]. The T3/7 phage showed altered adsorp-
tion efﬁciencies in four strains of E. coli when compared
to wild-type T3, which indicated that the host-range had
become more T7-like upon integration of the T7-like
gp17 tail ﬁber. However, when the plating efﬁciencies
(EOP) of wild-type T7 and T3 phages and the T3/7 phage
were compared in the male K91 strain of E. coli, the EOP
of T3/7 was 100-fold higher than T7 and 10,000-fold
higher than T3 [41]. This result shows that whilst
exchange of tail ﬁbers may be a key starting point in
host-range modiﬁcation, altered adsorption characteristics
may lead to unforeseen interactions with other properties
of the phage. In this case, once adsorption efﬁciencies had
been improved on the male strain, the presence or
activation of genes in the hybrid T3/7 phage mediated
escape from F exclusion with an efﬁciency not observed
in either wild-type parental phage, and this property acted
as a secondary mechanism to broaden the phage host-
range. The basic principles of creating T7 and T3 hybrids
was greatly expanded upon in the work of Ando et al.
where variants of both T7 and T3 were created by direct
genome manipulation in yeast [42]. Here both T3 with
T7-like gp17 and T7 with T3-like gp17 were generated,
and these showed the expected changes in plating
efﬁciencies on different strains of E. coli. The work was
then expanded into modiﬁcation of T3 gp17 to match the
sequence of gp17 from the Y. pseudotuberculosis phage
R, which expanded the T3 host-range to match that of
phage R whilst still retaining the lytic function of T3 and
its wild-type ability to infect E. coli. Finally, the transfer
of the gp17 from T7-like Klebsiella phage K11 into T7
highlighted the interesting compatibility issues that can
arise from the transfer of tail ﬁber genes between
bacteriophages. In this case it was not possible to generate
infectious T7 phage with gp17 from K11. It appears that
this is due to incompatibility between tail ﬁbers of K11
and the ‘collar’ assembly that mediates attachment of the
tail ﬁbers to the head of the bacteriophage. This meant
that generating a modiﬁed T7 with the ability to infect
Klebsiella required not only the gp17 gene of K11, but
also replacement of the ‘collar’ genes gp11 and gp12 with
those from K11. However, once the both ‘collar’ and tail
ﬁber genes had been altered, this newly modiﬁed T7
phage was able to infect and kill Klebsiella, suggesting
that the modiﬁed T7 retained its lytic properties even after
shifting hosts from E. coli [42].
Of course, attachment and genome delivery is only the
ﬁrst stage at which phages interact with the host; lysogeny
or lytic replication and assembly of phage progeny will
require interactions with a huge variety of host proteins
and pathways to complete the life-cycle. To give an
example, an extensive number of known interactions
between the phage lambda and E. coli have been reviewed
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by Friedman [43]. Therefore, it is likely that to a certain
degree the bacteriophage genome will become specialised
in order to mediate host-speciﬁc interactions, for example
within the lambda-like family of E. coli tailed-phages
there are cases where phages show a convincing genome
mosaic relationship to the lambda-family, but with altered
species speciﬁcity and highly divergent nucleotide
sequences [44,45]. Therefore in the future more funda-
mental work is required to investigate the underlying
mechanisms of phage-host interactions in order to better
understand the ways in which the phage genome may
adapt at other stages of its life-cycle. Although direct
manipulation of these interactions through traditional
genetic engineering may be difﬁcult, modern synthetic
biology methodologies such as directed evolution, may
allow us to rapidly adapt and modify phage to a desired
host in vitro [46,47]. The ability to modify or control these
interactions may play a key role in our ability to engineer
phage speciﬁcity beyond control of attachment and entry.
ENGINEERING PHAGE LONGEVITY
in vitro AND MINIMISING NEGATIVE
PATIENT-PHAGE INTERACTIONS
Utilising phages in a clinical setting presents challenges
that are not typically relevant to drug-based approaches.
For example, how can the patient immune response to
phages be minimised and how can phage persistence in
patients be increased to maximise the potential for
infection of the bacterial target. In addition, there are
also concerns regarding the clinical effects of the induction
of bacterial lysis by phages, which may release large
amounts of bacterial substances such as lipopolysacchar-
ide (LPS/endotoxin) or other pathogen-associated mole-
cular patterns (PAMPS) into the phage treated patient.
Release of PAMPs such as endotoxins from gram-negative
bacteria could have immediate adverse effects on the
phage treated patient by stimulating acute and systemic
inﬂammatory immune responses [48] and phage therapy
trials in humans have made observational links between
endotoxin release and reports of negative post-treatment
side-effects [49]. However, the immune modulation effects
of both endotoxin release and the application of phage
could conceivably also have positive effects on patient
outcome, and therefore there may be an element of risk
and reward when treating bacterial infections with lytic
phages and, as with all therapeutics, a need to balance
potential toxicity against maximising positive patient
outcomes. It is also necessary to identify whether phage
isolated and considered for therapeutic use contain any
factors that act to enhance bacterial virulence upon
infection, with an extreme example being the Shiga
toxin-encoding phages of the lambda-family [50]. Utilis-
ing phages as antimicrobial agents therefore may not be as
simple as choosing a combination of strongly lytic phages,
or phages with a particularly useful host-range. These
considerations have led to the engineering of phages to
improve their bioavailability and to alter their methods of
killing bacteria becoming an active area of research. This
is further compounded by the safety concerns with using a
replicative and genetically plastic virus in a healthcare
context, as there is no guarantee that a replicative phage
delivered to the patient will be genetically stable in vivo or
whether it will lead to uncontrolled onward transmission
from the treated patient unless serious considerations have
been given to genetic manipulation of the phage to address
these risk factors [51].
The most well-deﬁned immune response to phage is
that of virus neutralising (VN) antibodies targeted against
tail ﬁbers. Binding of anti-tail antibodies to phage inhibits
virus binding to bacteria, and can render a phage
population entirely non-functional by reducing the
availability of unbound infective phages in the patient
[52,53]. However, this is certainly not the only immune
response to phage, and Sokoloff et al. have shown that
modiﬁcation of phage capsids by addition of C-terminal
lysine or arginine residues aids the phage in escaping
complement-mediated inactivation by binding C-reactive
protein [54]. Another study by Merril et al. utilised the
classical virological method of modiﬁcation/adaptation
by serial passage to isolate a lambda phage population
that was able to avoid the murine immune response,
speciﬁcally the action of the mononuclear phagocyte
system that typically leads to phage clearance [55].
Analysis of two of these ‘long-circulating’ mutants
identiﬁed a common mutation in the major capsid protein
E which increased phage concentrations in the blood at
18 hours post inoculation approximately 10,000-fold;
subsequent work then conﬁrmed that transfer of this
single mutation back into the wild-type lambda phage
conferred the full ‘long-circulating’ phenotype [55,56].
Similar results were obtained by Capparelli et al. who
found that serially passaged mutants of an environmental
isolate of an E. coli O157:H7 phage and a Staphylococcus
aureus phage were able to persist in the circulation up to
10 times longer (up to one month post-inoculation) than
the wild-type and, interestingly, did not induce the
formation of neutralizing antibodies [57,58]. A study by
Łusiak-Szelachowska et al. has analysed the presence of
phage neutralising antibodies in human patients under-
going phage therapy, and found that whilst the level of
antibody stimulation was inconsistent among the group,
12.3% of patients exhibited a strong phage neutralising
response upon treatment, although this did not exclude a
positive patient outcome [59]. It therefore may not be
necessary to engineer phage such as to reduce the anti-
phage immune response in all cases, and could depend on
the type of phage (replicative or non-replicative), the
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speciﬁc bacterial infection to be treated, route of
administration, and planned number of phage adminis-
trations per treatment. Minimising this response could
also be important in the context of the goals of producing
an engineered broad-spectrum phage as a therapeutic. If a
single phage is identiﬁed for use as a scaffold into which
broad host-range efﬁcacy can be engineered, it may be
reasonable to consider that this phage could subsequently
be used for multiple treatments of bacterial disease across
a patient’s life. In this case minimising immune reactivity
to the phage scaffold could be vital to maintaining
efﬁcacy upon re-administration.
A key issue in the ﬁeld is the potential risk to the patient
when treating bacteria with lytic phage which causes the
release of endotoxins upon large-scale bacterial lysis, as
outlined in reviews by Abedon et al. and Loc-Carillo &
Abedon [4,60]. Thankfully this is a problem to which our
increasing ability to modify and engineer structural and
regulatory components of the phage genome in order to
alter the phage life-cycle or deliver synthetic genes is well
suited. Through the modiﬁcation of lysogenic phages to
become toxic but remain non-lytic, or lytic phages to
become non-lytic but retain toxicity, it appears to be
possible to alleviate risks of endotoxin release. Hagens
and Bläsi demonstrated that the small non-lytic phage
M13 can be engineered to express one of two lethal
proteins upon infection [61]. Both engineered M13
phages expressing the R-gene from the BglII restriction-
modiﬁcation system of Bacillus globigii and a lambda-
derived holin were able to kill 99% of infected bacteria,
with endotoxin levels approximately 4-fold lower after
lysis when compared to a virulent lambda control.
However, a 99% killing rate appears to have been
insufﬁcient to prevent rapid re-growth of a bacterial
population that was resistant to subsequent infection by
the modiﬁed M13 phage. A similar methodology to the
above was used to develop a non-lytic and non-replicative
P. aeruginosa phage Pf3R, but in this case an essential
transport protein from ORF40 of Pf3 was truncated and
the R-gene of the BglII system added downstream,
rendering Pf3R non-replicative but toxic to bacteria not
harbouring the protective BglII methylase (M-) gene [62].
This study used in vivo testing of both wild-type Pf3 and
Pf3R in a murine peritonitis infection model and provided
data showing that both Pf3 and Pf3R are effective in
treating P. aeruginosa infection, with Pf3R improving
percentage of survival when higher inoculating doses of
bacteria were used. This result conﬁrms expectations that
the amount of endotoxin released following Pf3 lysis is
increased at high bacterial cell number, highlighting the
negative effects of lysis by the wild-type phage and the
difference in method of action between Pf3 and Pf3R. An
independent conﬁrmation of the potential importance of
using a non-lytic killing phage in vivo was provided by
Matsuda et al. who analysed the properties of the lysis-
deﬁcient T4 mutant T4LyD in comparison to wild-type T4
in a murine peritonitis model [63]. T4LyD contains an
amber mutation in the holin gene, producing a truncated,
non-functional holin, which ablates the ability of the
phage to lyse cells at the ﬁnal stage of replication.
Treatment of mice in an E. coli peritonitis model using the
T4LyD phage signiﬁcantly improved survival compared
to untreated mice and mice treated with wild-type T4,
with levels of inﬂammatory mediators such as tumor
necrosis factor alpha (TNF-α) and interleukin-6 (IL-6)
reduced 2-fold in T4LyD treated mice compared to
controls [63].
In a different non-lytic and non-replicative killing
strategy Westwater et al. utilised an M13-based phagemid
system to deliver a plasmid capable of inducible over-
expression of the toxic components of natural E. coli
conditionally lethal genes [64]. The beneﬁts of the
phagemid system are signiﬁcant in the context of
addressing some potential pitfalls of phage therapy. In
order to derive a phagemid, the necessary genes for
genome ampliﬁcation, capsid assembly and packaging,
and host lysis are supplied in trans, so whilst the
phagemid plasmid is packaged into a functional infectious
phage particle, this particle lacks multiple components
that are essential for onwards replication (Figure 2). This
system therefore prevents uncontrolled release of progeny
phages into the surrounding environment, and avoids
non-speciﬁc disruption of the bacterial cell wall and
subsequent release of endotoxins caused by the release of
the progeny phages. Westwater et al. showed that
infection of E. coli with M13 phagemids containing
either the gef or chpBK genes under control of the LacI
promoter led to a 99.99% drop in cell viability within 2
hours of IPTG induction [64]. Further work using M13
phagemids has yielded phages that are capable of
stimulating a lethal uncoupling of catabolism in patho-
genic E. coli O157:H7 by expressing a modiﬁed catabolic
activator protein (CAP) [65]. This paper also highlights
the importance of considering multiplicity of infection
(MOI) when utilising a phagemid system that is incapable
of replication in vivo, as killing efﬁciency dropped
dramatically when infections were carried out with an
MOI below 10, which is supported in a study carried out
by Kasman et al. that has experimentally validated a
model of how observed MOIs correspond to theoretical
MOIs in M13 and P1 phagemid infections [66]. Most
recently, Krom et al. have further extended the range of
non-lytic antimicrobial peptides that have been tested
using the M13 phagemid system [67]. The most
efﬁcacious phagemid vector expressed the antimicrobial
peptides cecropin and apidaecin in combination with the
bacterial toxin CcdB, and signiﬁcantly improved survival
in a murine peritonitis infection model. Interestingly,
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infection of mice with M13 phagemid not containing any
antimicrobial peptides or toxin did appear to have a
positive effect on mouse survival, although this effect was
not statistically signiﬁcant when compared to untreated
controls. It therefore may be interesting to consider
further investigation of whether the M13 delivery system
is capable of promoting host defence even in the absence
of a toxic payload, possibly by recruiting immune cells to
the site of bacterial infection, or whether M13 attachment
and phagemid injection has other subtle effects on
bacterial viability in vivo.
UTILISING BACTERIOPHAGES TO
ENGINEER BACTERIAL TREATMENT
SUSCEPTIBILITY AND MODIFY THE
BACTERIAL GENOME
The huge success and efﬁcacy of treatment of bacterial
disease with antibiotic drugs is unprecedented, with the
ubiquitous nature of bacterial interaction with human and
animal health meaning that their impact on healthcare has
been immense. The broad-spectrum efﬁcacy of antibiotics
Figure 2. Schematics showing the two methods for phagemid packaging into infectious phage particles. In (A) helper
plasmid is co-transformed into the phage production cell along with the phagemid. This helper plasmid is capable of expressing all
essential genes necessary for phage assembly, replication of the phagemid into a form that can be packaged into the phage capsid,
and exit of progeny phages from the host. Therefore upon co-transformation the production cell is capable of [often inducible]
production of progeny phages packaged with the phagemid ready for puriﬁcation and subsequent infections. In (B) the phage
production cell is ﬁrst lysogenised with a lysogenic phage. This lysogen can subsequently be transformed with the phagemid
construct, and contains the entire phage genome. Upon induction of lysis, the lysogen will begin to express these genes, and
concurrently amplify and package both the lysogen DNA and the phagemid into progeny phage. This mixed population of lysogenic
and phagemid-packaged progeny phages will be released upon completion of lysis, and can subsequently be puriﬁed and used in
subsequent infections.
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is however both a gift, with healthcare practitioners able
to choose medication in the knowledge they will treat
disease even without a speciﬁc bacterial diagnosis, and a
curse, with a large pool of susceptible bacteria all
undergoing strong selection to escape drug action and
acquire resistance upon antibiotic treatment [6]. Horizon-
tal gene transfer between bacteria also means that any
emerging resistance mutation of mobile genetic element
conferring resistance can be rapidly disseminated
amongst various bacterial species. Another important
effect of antibiotic treatment is that disruption of
commensal ﬂora may predispose the patient to secondary
infection, as more robust or treatment-resistant patho-
genic bacteria can rapidly ﬁll empty niches left by killed
commensal bacteria [68]. These observations have led to
two major avenues of investigation in the context of
bacteriophage therapies (Figure 3). Firstly is it possible to
utilise phages with broad host speciﬁcity that subse-
quently show a degree of strain-speciﬁcity in their action
of killing? Secondly, can phages be used to modify the
genomes of bacteria such that they generate susceptibility
to subsequent treatment, possibly by employing such a
strategy as part of a combination treatment strategy?
With ﬂexible packaging limits and promiscuity in terms
of genome packaging, bacteriophages have been identi-
ﬁed as an ideal carrier to deliver foreign genes and
constructs into bacteria in situations where direct
transformation is impossible. The rapid development of
sequence speciﬁc RNA-guided nucleases such as the
CRISPR-Cas9 system [69] has also meant that phage-
mediated genome-speciﬁc targeting of bacteria is becom-
ing a realistic goal, with two major publications produced
in this area. Firstly, Citorik et al. used CRISPR targeting
RNAs (crRNA(s)) to enable the Cas9 endonuclease to
restore carbenicillin susceptibility to resistant E. coli,
target DNA gyrase (gyrA) mutants resistant to quinolone
antibiotics, and also delete an intimin-encoding chromo-
somal virulence gene eae from Enterohaemorrhagic
E. coli (EHEC) O157:H7 [70]. Delivery was achieved
using an M13 phagemid system, with a high transduction
and cutting efﬁciency of between 99% and 99.99%
observed in vitro. In the case of cutting the episomal
resistance plasmid pNDM-1, the presence of a plasmid-
borne toxin-antitoxin system, by which stability of
episomal elements can be enhanced by post-segregational
killing of daughter cells lacking the plasmid, appears to
have led to selective killing of bacteria after phagemid
delivery due to plasmid loss rather than antibiotic re-
sensitisation. The effect of eae disruption was also tested
in a Galleria mellonella larval infection model to
investigate whether phage treatment of infected G.
mellonella larvae correlates leads to decreased bacterial
pathogenicity in vivo. In this case, whilst there was a
signiﬁcant difference in survival between the larvae
treated with eae-targeting phagemid compared to the
untreated and non-targeting control, survival was not
enhanced to a large degree. This may again highlight the
difﬁculties in achieving a high MOI and infection rate in
vivo and how this can limit the efﬁcacy of non-replicative
phage treatments. The second major publication, by
Bikard et al., used chromosome and episome-speciﬁc
crRNA targeting to selectively kill antibiotic-resistant
Staphylococcus aureus strains [71]. A staphylococcal
phagemid delivery system was developed based on the
phage FNM1, with the phagemid carrying the Cas9
endonuclease together with crRNAs targeting either the
chromosomally-located aph-3 kanamycin resistance
gene, the methicillin resistance gene mecA in the MRSA
strain USA300Φ, or the USA300 virulence plasmids
pUSA01 and pUSA02. When treating the aph-3 carrying
S. aureus with the FNM1 phagemid in vitro, reduction in
viable cell counts by 99.99% was observed. When
targeting the MRSA strain USA300Φ and its virulence
plasmids pUSA01 and pUSA02, reductions in cell
viability under selective conditions (the presence of
oxacillin or tetracycline respectively) were observed to
be between 99%–99.9%. Interestingly, the authors also
considered the use of phagemid as a mechanism of
bacterial immunisation, with RN4220 cells treated with
the mecA-targeting construct unable to subsequently
inherit the pUSA02 virulence plasmid. An in vivo test
of the aph-3 targeting efﬁcacy of the FNM1 phagemid
was carried out using a mouse skin colonisation model. In
this case reduction in numbers of viable aph-3 positive
cells was not reduced to a similar degree as observed in in
vitro studies, with a 77% reduction in the numbers of
viable kanamycin-resistant bacteria after in vivo treat-
ment. However, this was signiﬁcantly different to other
experimental conditions, showing that the phagemid is
capable of infection and sequence-speciﬁc gene targeting
in vivo. A study by Yosef et al. has modiﬁed the genome
of lambda phage to include a type I-E CRISPR system
along with spacer sequences targeting, and thus prevent-
ing transformation of, lambda-lysogenised E. coli with
antibiotic resistance plasmids [72]. Interestingly, they also
considered methods by which maintenance of this
modiﬁed lambda lysogen could confer a selective
advantage to the lysogenised E. coli. By adding
protospacers targeting synthetic sequences within a
modiﬁed lytic phage, they were able to confer resistance
to phage infection to the lysogen, meaning that the
proportion of modiﬁed lysogens within a mixed bacterial
population could be enriched through infection with the
lytic phage, with lysogens showing enhanced resistance
to lysis compared to wild-type bacteria. The leveraging of
sequence-speciﬁc targeting in phage-mediated treatment
of bacterial disease is still at a very early stage in terms of
testing feasibility and efﬁcacy. However, it does offer an
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Figure 3. Schematics summarizing methods for modiﬁcation of the host genome and engineering altered bacterial
sensitivity used for onwards treatment after infection with a genetically engineered phage. Genes can be introduced to
infected bacteria in the form of a modiﬁed lysogen or a phagemid vector. Expression of genes from these sources can either be used
to directly kill bacteria, for example by using conditional lethality genes from toxin-antitoxin systems, or to sensitise the bacteria to
onwards treatment such as with dominant sensitive genes. A second option is to introduce a gene editing system such as CRISPR-
Cas9, where upon phagemid or lysogen entry, genetic markers can be speciﬁcally targeted and thereby inactivated. This allows for
the killing or modiﬁcation of bacteria in a sequence-dependent manner, minimising the risks of disruption in non-targeted commensal
bacterial populations.
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interesting alternate approach to traditional bacteriophage
treatments, especially in the context of phagemid delivery
systems. Here it is possible to imagine that concerns
regarding host-speciﬁc interactions at the level of phage
replication could be mitigated by the use of a non-
replicative system which also offers control over such
features as broad-spectrum origins of replication and
promoters at the level of phagemid design. This could
leave researchers free to concentrate on methods of
increasing host-range and infection efﬁciency through
modiﬁcation of features associated with attachment and
injection, which as discussed above is a key consideration
that the ﬁeld is currently investigating.
Whilst the body of evidence regarding phage therapies
is still expanding and developing, it appears that at this
stage the ability to utilise phages to reach a level of
efﬁcacy seen when using antibiotic drugs is beyond our
current level of understanding. This conclusion had led to
the investigation of whether phages can also be useful as
part of combination therapies with traditional antimicro-
bials to enhance sensitivity or re-introduce sensitivity into
strains of bacteria which have become resistant to current
treatment regimes. A number of different approaches have
been considered regarding how phages can best be
utilised as part of combination therapies (Figure 3).
Yacoby et al. have chemically modiﬁed ﬁlamentous
phages to speciﬁcally deliver antibiotic drugs to Staphy-
lococcus, Streptococcus and E. coli bacteria [73].
Although strictly speaking this is a chemical rather than
a genetic engineering approach to the problem, by
combining anti-bacterial polyclonal IgG antibodies
bound to the minor phage coat protein p3 with
chloramphenicol chemically attached to the major coat
protein p8 it was possible to increase the potency of the
antibiotic 10,000-fold compared to treatment with
chloramphenicol alone. A more relevant approach in the
context of this review was taken by Lu and Collins. Here
the genome of M13 phage was modiﬁed to deliver the
lexA3 gene, which encodes a repressor of the bacterial
SOS DNA repair system [74] and increases the sensitivity
of bacteria to antibiotics such as quinolones that cause
DNA damage as part of their antimicrobial action (as
topoisomerase LT inhibitors). Upon infection with the
modiﬁed M13 phage, sensitivity to oﬂoxacin was
increased between 2.7- to 4.5-fold. The phage-mediated
enhancement of oﬂoxacin efﬁcacy was also tested in vivo
in a murine intraperitoneal infection model. Here an
increase in mouse survival from 20% to 80% was
observed in mice treated with both the engineered
phage and oﬂoxacin when compared to oﬂoxacin
treatment alone. Interestingly, the difference in survival
rates between treatment with wild-type phage and
oﬂoxacin compared to engineered phage and oﬂoxacin
was reduced to 30%, indicating that wild-type phage
alone had a potentiating effect on the antibiotic efﬁcacy.
In a similar study, Edgar et al. modiﬁed the genome of
lambda phage to introduce the antibiotic sensitising genes
rpsL and gyrA, which are expressed upon lysogeny [75].
When antibiotic resistant E. coli mutants were lysogen-
ised with the modiﬁed lambda phage, antibiotic sensitiv-
ity was restored, with minimum inhibitory concentrations
of streptomycin and nalidixic acid decreasing 8- and 2-
fold respectively. As a side point from this paper,
considerations were also given as to how best to allow
selection for the modiﬁed lysogen without introducing an
additional antibiotic selection marker. This is a key
consideration when using phage to remove resistance
genes, as removal of one marker cannot be traded for the
introduction of another. Here overexpression of the tehAB
gene from a T7 promoter, which confers resistance to the
toxic tellurium compound tellurite, was successfully
substituted for a chloramphenicol resistance cassette.
Finally, a study has also investigated the use of phagemid-
mediated RNA silencing to reduce transcription from
antibiotic resistance genes [76]. Unfortunately, it appears
that the RNA silencing of resistance genes is not a highly-
efﬁcient process, with only 29% of bacteria positive for
the phagemid showing increased sensitivity to the
antibiotic. When compared to more recent work on
cas9-mediated gene targeting, this appears to be a more
challenging avenue of investigation.
CONCLUSIONS
The goal of this article was to highlight key examples
from the literature on how bacteriophages have been
modiﬁed to increase their utility as antimicrobials in a
healthcare context. The combination of improved tools
for genome analysis and modiﬁcation along with the
increasing threat of widespread antibiotic resistance
amongst diverse microbes has led to a long-overdue
resurgence of phage research. Whilst worries regarding
the efﬁcacy, safety and usefulness of phage therapies do
remain, these problems are now being investigated, and
with modern tools it may ﬁnally be possible to address
these concerns. Although there may not be one obvious
single solution attempts to combine research insights from
multiple areas into a single phage backbone may yield
exciting results.
Since biological containment and control is an
important consideration, especially in the context of
genetically engineered organisms and viruses, it appears
that non-replicative phagemid systems may offer an ideal
opportunity to address these issues, with the M13
phagemid system being especially well suited to deliver-
ing promising results. The phagemid system also opens
the possibility of rescuing phages from highly-modiﬁed
specialised lysogens or helper-plasmids, which could
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make the manipulation of phage components such as tail
ﬁbres and capsids easier to achieve, whilst also offering
complete control over the genetic material delivered upon
phage infection. However, this enthusiasm must be
tempered by the fact that non-replicative systems may
make it extremely difﬁcult to achieve a therapeutic dose
of phages in vivo.
Despite recent efforts, the issues of application,
delivery and control are still relevant to both genetically
modiﬁed and wild-type phage, and as such these are
currently likely to be more useful for topical site-speciﬁc
treatments such as surgical wounds and burns, or as a
method for preventing bacterial infection at interfaces
between biological and material surfaces. However, the
consideration of phage use as a more broad-spectrum
treatment should not be discounted, with emerging
possibilities for modifying and removing deleterious
marker sequences from a large bacterial population
without the need for a general bacterial killing mechanism
being an enticing prospect. There have been a number of
recent examples that the bacterial CRISPR system can be
effectively integrated into both phage and phagemid
genomes, and although there may be numerous chal-
lenges in utilising phages to signiﬁcantly modify the vast
bacterial populations found in both animals and humans,
the opportunities for control and targeted removal of
genetic features in bacteria are exciting.
Overall, the recent resurgence of interest in phages, and
the ways in which we may be able to control and modify
their properties and behaviour as antimicrobials, is of
great interest and potential importance. There have been a
number of exciting developments in the ﬁeld, with only a
selection of these developments highlighted in this
review. There are signiﬁcant differences between even a
non-replicative phagemid and an antimicrobial drug
treatment; how these differences are reconciled within
the current pharmaceutical testing, licensing and ‘Good
Manufacturing Practices’ (GMP) framework will be
interesting and possibly signiﬁcantly impact the direction
of future applied phage research [36,77]. Also, many of
the phage engineering solutions discussed here would
give rise to what would be considered a genetically-
modiﬁed organism (GMO) and as such the licensure and
clinical use of these phage would be tightly regulated.
There has been some review of the safety and licencing
GMO’s in the context of bacterial vaccines [78] and
replicative viral vaccines derived from recombinant
DNA, such as the live-attenuated Inﬂuenza A and B
vaccine Flumist®/Fluenz®, are currently licenced for use
in the US [79] and Europe [80]. Therefore whilst extra
considerations must be made, such as the potential
transmissibility and dissemination of a GMO phage
beyond the treated patient and the ability of the modiﬁed
features to transfer to naturally-occurring phages, this
may not be an absolute limitation on their potential
therapeutic use. Hopefully continued research support in
this area will allow the ﬁeld to continue to address
concerns regarding phage therapies, and ﬁnally unlock
their signiﬁcant potential as antimicrobial agents to
enhance human and animal health.
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